Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Nanomedicine ; 9: 2439-58, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24920895

RESUMO

Topical application of antifungals does not have predictable or well-controlled release characteristics and requires reapplication to achieve therapeutic local concentration in a reasonable time period. In this article, the efficacy of five different US Food and Drug Administration-approved antifungal-loaded (amphotericin B, natamycin, terbinafine, fluconazole, and itraconazole) electrospun gelatin fiber mats were compared. Morphological studies show that incorporation of polyenes resulted in a two-fold increase in fiber diameter and the mats inhibit the growth of yeasts and filamentous fungal pathogens. Terbinafine-loaded mats were effective against three filamentous fungal species. Among the two azole antifungals compared, the itraconazole-loaded mat was potent against Aspergillus strains. However, activity loss was observed for fluconazole-loaded mats against all of the test organisms. The polyene-loaded mats displayed rapid candidacidal activities as well. Biophysical and rheological measurements indicate strong interactions between polyene antifungals and gelatin matrix. As a result, the polyenes stabilized the triple helical conformation of gelatin and the presence of gelatin decreased the hemolytic activity of polyenes. The polyene-loaded fiber mats were noncytotoxic to primary human corneal and sclera fibroblasts. The reduction of toxicity with complete retention of activity of the polyene antifungal-loaded gelatin fiber mats can provide new opportunities in the management of superficial skin infections.


Assuntos
Antifúngicos/administração & dosagem , Antifúngicos/química , Preparações de Ação Retardada/química , Fungos/fisiologia , Gelatina/química , Membranas Artificiais , Materiais Biocompatíveis , Sobrevivência Celular/efeitos dos fármacos , Preparações de Ação Retardada/administração & dosagem , Difusão , Sinergismo Farmacológico , Galvanoplastia/métodos , Fungos/efeitos dos fármacos , Nanocápsulas/administração & dosagem , Nanocápsulas/química , Rotação
2.
Dis Model Mech ; 6(5): 1146-58, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-23649821

RESUMO

Myopia is a huge public health problem worldwide, reaching the highest incidence in Asia. Identification of susceptible genes is crucial for understanding the biological basis of myopia. In this paper, we have identified and characterized a functional myopia-associated gene using a specific mouse-knockout model. Mice lacking the muscarinic cholinergic receptor gene (M2; also known as Chrm2) were less susceptible to lens-induced myopia compared with wild-type mice, which showed significantly increased axial length and vitreous chamber depth when undergoing experimental induction of myopia. The key findings of this present study are that the sclera of M2 mutant mice has higher expression of collagen type I and lower expression of collagen type V than do wild-type mice and mice that are mutant for other muscarinic subtypes, and, therefore, M2 mutant mice were resistant to the development of experimental myopia. Pharmacological blockade of M2 muscarinic receptor proteins retarded myopia progression in the mouse. These results suggest for the first time a role of M2 in growth-related changes in extracellular matrix genes during myopia development in a mammalian model. M2 receptor antagonists might thus provide a targeted therapeutic approach to the management of this refractive error.


Assuntos
Progressão da Doença , Miopia/metabolismo , Miopia/patologia , Receptor Muscarínico M2/metabolismo , Adulto , Idoso , Alcaloides/farmacologia , Alcaloides/uso terapêutico , Animais , Proliferação de Células/efeitos dos fármacos , Colágeno/genética , Colágeno/metabolismo , Matriz Extracelular/efeitos dos fármacos , Matriz Extracelular/metabolismo , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Fibroblastos/patologia , Furanos/farmacologia , Furanos/uso terapêutico , Técnicas de Silenciamento de Genes , Humanos , Camundongos , Camundongos Knockout , Pessoa de Meia-Idade , Miopia/tratamento farmacológico , Naftalenos/farmacologia , Naftalenos/uso terapêutico , Piperidinas/farmacologia , Piperidinas/uso terapêutico , Pirenzepina/análogos & derivados , Pirenzepina/farmacologia , Pirenzepina/uso terapêutico , RNA Interferente Pequeno/metabolismo , Receptor Muscarínico M2/antagonistas & inibidores , Receptor Muscarínico M2/genética , Esclera/efeitos dos fármacos , Esclera/metabolismo , Esclera/patologia , Regulação para Cima/efeitos dos fármacos
3.
Mol Vis ; 18: 1436-48, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22736935

RESUMO

PURPOSE: The aim of this study was to identify the genes and pathways underlying the growth of the mouse sclera during postnatal development. METHODS: Total RNA was isolated from each of 30 single mouse sclera (n=30, 6 sclera each from 1-, 2-, 3-, 6-, and 8-week-old mice) and reverse-transcribed into cDNA using a T7-N(6) primer. The resulting cDNA was fragmented, labeled with biotin, and hybridized to a Mouse Gene 1.0 ST Array. ANOVA analysis was then performed using Partek Genomic Suite 6.5 beta and differentially expressed transcript clusters were filtered based on a selection criterion of ≥ 2 relative fold change at a false discovery rate of ≤ 5%. Genes identified as involved in the main biologic processes during postnatal scleral development were further confirmed using qPCR. A possible pathway that contributes to the postnatal development of the sclera was investigated using Ingenuity Pathway Analysis software. RESULTS: The hierarchical clustering of all time points showed that they did not cluster according to age. The highest number of differentially expressed transcript clusters was found when week 1 and week 2 old scleral tissues were compared. The peroxisome proliferator- activated receptor gamma coactivator 1-alpha (Ppargc1a) gene was found to be involved in the networks generated using Ingenuity Pathway Studio (IPA) from the differentially expressed transcript cluster lists of week 2 versus 1, week 3 versus 2, week 6 versus 3, and week 8 versus 6. The gene expression of Ppargc1a varied during scleral growth from week 1 to 2, week 2 to 3, week 3 to 6, and week 6 to 8 and was found to interact with a different set of genes at different scleral growth stages. Therefore, this indicated that Ppargc1a might play a role in scleral growth during postnatal weeks 1 to 8. CONCLUSIONS: Gene expression of eye diseases should be studied as early as postnatal weeks 1-2 to ensure that any changes in gene expression pattern during disease development are detected. In addition, we propose that Ppargc1a might play a role in regulating postnatal scleral development by interacting with a different set of genes at different scleral growth stages.


Assuntos
Proteínas do Olho/genética , Regulação da Expressão Gênica no Desenvolvimento , Redes Reguladoras de Genes , Genoma , Esclera/metabolismo , Transativadores/genética , Animais , Animais Recém-Nascidos , Proteínas do Olho/metabolismo , Perfilação da Expressão Gênica , Camundongos , Camundongos Endogâmicos BALB C , Família Multigênica , Análise de Sequência com Séries de Oligonucleotídeos , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , RNA Mensageiro , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Esclera/crescimento & desenvolvimento , Software , Fatores de Tempo , Transativadores/metabolismo , Fatores de Transcrição
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...